


How Does the Immune System Combat Cancer?

As the body's defense force, the immune system recognizes and combats pathogens through 2 lines of defense:



Normally troops destroy the mutant "cancerous" cells that may appear; however, cunning cancer cells can appear "friendly" to evade detection and pursuit.

Immunotherapies for Hematological Cancers

"Immunotherapy" helps the immune system recognize cancer cells and augments its response to destroy them.

Currently there are 6 main types of immunotherapies for hematological cancers:

The second contract of	i.e., bone marrow transplantation (BMT)	
ntibody drugs	Antibody-drug conjugates (ADC)Bispecific antibody drugs	
	Bolster the immune system's anti-cancer effects	
ncer vaccines	Incorporate cancer cell antigens that trig- ger an immune attack	
Cell therapy technique (AIET) (Not genetica- Ily modified)	Draw blood, isolate immune cell troops for "training" ex vivo, and inject strengthened cells back into the body to kill cancer cells.	
Chimeric antigen receptor T-cell therapy (CAR-T) (Genetically modified)	Draw blood, isolate T cells, "modify" and equip them ex vivo with radar and mechanical arms, and inject them into the body to replicate en masse, allowing precise cancer cell recognition and destruction.	
	technique (AIET) (Not genetica- lly modified) Chimeric antigen receptor T-cell therapy (CAR-T) (Genetically	


★ Highly discussed

CAR-T therapy features cell modification, strengthening, and precise attacks, offering new hope for refractory hematological cancers; following domestic approval at certain hospitals, CAR-T therapy has sparked much discussion.

Who Is Eligible for CAR-T Treatment?

Currently the most commonly used and best-developed form of CAR-T targets cancers arising from immune B cells (i.e., cancerous B cells).

B cells have specific markers. Modifying T cells to recognize these markers and infusing them into the body allows them to kill cancerous B cells with these specific markers.




CAR-T therapy indications:

Immune B cell-derived cancers	Lymphoma	*Diffuse large B-cell lymphoma(DLBCL)	
		Mantle cell lymphoma (MCL)	
		Follicular lymphoma (FL)	
		Primary mediastinal large B cell lymphoma (PMBL)	
	Leukemia	*Acute lymphoblastic leukemia (ALL)	
	Multiple myeloma (MM)		

Note: *CAR-T indications currently approved in Taiwan

How Is CAR-T Implemented?

- Number of treatment cycles: One. You may discuss with your doctor whether to collect and freeze cells in advance for leukapheresis, to preserve T cells with better activity.
- Treatment length: About 1.5 months. The complex CAR-T treatment course requires precision equipment and strict quality control at every step.



Potential Adverse Effects (AEs) of **CAR-T Therapy**

When the modified CAR-T cells attack cancer cells, excessive expansion may cause a dramatic immune response; such AEs often occur within 2 weeks of infusion.

In addition, CAR-T cells may suppress normal B cell function, so patients should watch out for infection after CAR-T therapy.

Potential AEs of CAR-T therapy:

Cytokine release syndrome (CRS)

- Fever
- Shortness of breath
- Hypotension
 Coma



Immune effector cell-associated neurotoxicity syndrome (ICANS)

Symptoms of central neurotoxicity caused by immune cells include:

- Headaches

Tremors

- Dizziness
- Irritability
- Seizures
- Aphasia
- Delirium (sudden-onset cerebral cognitive deficits)
- Impaired consciousness



Hemophagocytic syndrome (Less common)

Abnormally activated WBCs attack the body itself and ingest other blood cells. Symptoms include:

Fever

- Jaundice
- Hepatosplenomegaly
 Organ failure



Lymphadenopathy

International treatment guidelines in accordance with the severity of CAR-T-induced AEs are currently available. Medical teams can prevent and precisely manage associated AEs.

Comparing CAR-T and Traditional Immunotherapy

CAR-T therapy is completely different from traditional methods. It only requires one cycle, but its high cost poses a great challenge for patients.

	Immune drug therapy	Cell therapy	CAR-T cell immunotherapy
Treatment mechanism	Remove the brakes on T cell troops to let them actively recognize and attack cancer cells	Isolate immune cells (e.g., NK cells), train them ex vivo, and inject them back to des- troy cancer cells	Isolate immune T cells, perform genetic modification, and infuse them back, greatly improving cancer cell recognition and destruction capabilities
Treatment frequency	Multiple cycles approx. once every 2-3 weeks.	Approx. 6 doses per cycle; may induce immune memory in a subset of immune cells	Continual effects after just 1 cycle (1 injection)
Regulations	TFDA-approved	In accordance with the Regulations of Special Medical Techniques	TFDA-approved
Treatment costs	Approx. NT\$150,000 per cycle; meets NHI coverage criteria for certain conditions	NT\$1-2 million per cycle; no NHI coverage	More than NT\$10 million per cycle; no NHI cove- rage
Health care facility availability	Most major hospitals	20+ approved hospitals	Only a few medical centers



In order to choose the most suitable treatment for your condition, we recommend discussing in full detail with your primary physician and care team all the available options!



A distinguished physician thoroughly explains CAR-T treatment



A smart helper for cancer patients-Download the **HOPE** Passport app for free

Facilitating smooth patient-doctor communications



Strategies Against Hematological Cancers Lymphomas



Strategies Against



HOPE Foundation for Cancer Care helpline for free counseling: 0809-010580



